```html

Zollinger‑Ellison Syndrome (Gastrinoma) – A Comprehensive Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more tumors called gastrinomas form in the pancreas, duodenum, or, less commonly, the stomach. These tumors secrete excessive amounts of gastrin, a hormone that stimulates the stomach lining to produce large volumes of gastric acid. The resulting hyperacidity leads to severe peptic ulcers, pain, and a host of gastrointestinal symptoms.

Who it affects

• Both sexes equally, though some series report a slight male predominance (≈55 %).
• Typical age at diagnosis is 40–60 years, but cases have been reported from adolescence to the elderly.

Prevalence

• Overall incidence is about 0.5–2 cases per million persons per year.<sup>[1]</sup>
• Approximately 25 % of gastrinomas occur as part of the inherited condition multiple endocrine neoplasia type 1 (MEN‑1).

Symptoms

Because hyperacidic secretions affect the entire upper gastrointestinal (GI) tract, the symptom profile can be broad. Symptoms may be intermittent at first and become more constant as the tumor grows.

Gastro‑intestinal symptoms

• Recurrent or refractory peptic ulcers – often multiple, large, and located beyond the duodenum (e.g., jejunal ulcers).
• Abdominal pain – burning or cramping pain that may improve after meals (due to ulceration) or worsen with food (due to acid load).
• Diarrhea – occurs in 30‑50 % of patients; acid inactivates pancreatic enzymes and damages the mucosa, leading to malabsorption.
• Steatorrhea (fatty stools) – a consequence of fat malabsorption from acid‑induced pancreatic enzyme inactivation.
• Nausea & vomiting – especially after large meals.
• Weight loss – secondary to malabsorption and chronic GI discomfort.

Systemic & extra‑intestinal symptoms

• Heartburn/acid reflux – due to the massive acid load.
• Gastro‑intestinal bleeding – melena or hematemesis from ulcer erosion.
• Fatigue & anemia – from chronic blood loss.
• Bone pain or fractures – long‑standing malabsorption can lead to vitamin D deficiency and osteoporosis.

Causes and Risk Factors

Primary cause

ZES is caused by gastrinomas, neuroendocrine tumors that arise from the G-cells of the pancreas or duodenum. These tumors secrete gastrin autonomously, bypassing normal regulatory feedback.

Genetic risk factors

• Multiple Endocrine Neoplasia type 1 (MEN‑1) – an autosomal‑dominant mutation in the MEN1 gene; 20‑30 % of ZES patients have MEN‑1.
• Familial gastrinoma syndrome – rare, inherited form not linked to MEN‑1.

Other risk factors

• Age > 40 years (higher likelihood of sporadic gastrinomas).
• History of chronic gastritis or H. pylori infection does not cause ZES but can mask its symptoms.

Diagnosis

Diagnosing ZES requires a combination of biochemical testing, imaging, and sometimes endoscopic evaluation. The goal is to confirm hypergastrinemia, demonstrate acid hypersecretion, and locate the tumor.

1. Biochemical tests

• Fasting serum gastrin level – a level > 1000 pg/mL (≥ 10 × upper limit of normal) in the presence of gastric acidity is highly diagnostic.<sup>[2]</sup>
• Secretin stimulation test – paradoxical rise in gastrin after IV secretin administration (≥ 120 pg/mL rise) confirms gastrinoma when basal levels are equivocal.
• pH testing – gastric pH < 2 confirms acid hypersecretion.

2. Imaging studies (tumor localization)

• Somatostatin receptor scintigraphy (SRS) / Ga‑68 DOTATATE PET‑CT – most sensitive for neuroendocrine tumors; detects lesions as small as 5 mm.
• Endoscopic ultrasound (EUS) – excellent for small pancreatic lesions.
• CT or MRI abdomen – used for staging and to assess metastatic spread, especially to the liver.

3. Endoscopic evaluation

• Upper endoscopy (EGD) – visualizes ulcers, obtains biopsies to rule out H. pylori, and can sample suspicious lesions.

4. Genetic testing (when indicated)

If there is a personal or family history suggestive of MEN‑1, testing for MEN1 mutations is recommended.

Treatment Options

Therapy is aimed at two goals: control of acid hypersecretion and removal or control of the tumor. A multidisciplinary team—gastroenterology, endocrine surgery, oncology, and nutrition—is ideal.

1. Acid‑suppression medications

• Proton pump inhibitors (PPIs) – high‑dose omeprazole, esomeprazole, or pantoprazole are first‑line. Doses often exceed standard ulcer therapy (e.g., omeprazole 60–120 mg/day). PPIs quickly normalize gastric pH, heal ulcers, and relieve symptoms.
• H2‑receptor antagonists – can be used adjunctively, but PPIs are superior for ZES.
• Long‑term PPI use requires monitoring for hypomagnesemia, B12 deficiency, and bone health.

2. Surgical management

• Enucleation – removal of small, localized gastrinomas (< 2 cm) without surrounding tissue.
• Pancreaticoduodenectomy (Whipple procedure) – for larger or infiltrating tumors in the pancreatic head.
• Distal pancreatectomy – for tumors in the pancreatic body/tail.
• Surgery is curative in ~30‑40 % of sporadic cases; metastatic disease often requires additional therapy.

3. Medical therapy for unresectable or metastatic disease

• Somatostatin analogs (octreotide, lanreotide) – inhibit gastrin secretion and can shrink neuroendocrine tumors.
• Targeted therapy (everolimus, sunitinib) – approved for progressive pancreatic neuroendocrine tumors.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE delivers radiation directly to tumor cells expressing somatostatin receptors.
• Chemotherapy – reserved for high‑grade neuroendocrine carcinomas; regimens such as streptozocin + 5‑FU.

4. Lifestyle and supportive measures

• Small, frequent meals low in fatty content to reduce acid stimulation.
• Avoidance of NSAIDs, alcohol, and tobacco, all of which worsen ulcer disease.
• Supplementation with calcium, vitamin D, and possibly B12 if on chronic PPIs.
• Regular surveillance endoscopy (every 1–2 years) to monitor ulcer healing and detect new lesions.

Living with Zollinger‑Ellison Syndrome (gastrinoma)

While ZES is a chronic condition, most patients lead active lives with proper management.

Medication adherence

• Take PPIs exactly as prescribed—usually twice daily for the first several weeks, then taper to the lowest effective dose.
• Set daily reminders; missing a dose can rapidly cause acid rebound and ulcer recurrence.

Nutrition tips

• Eat low‑fat, low‑spice foods; fats stimulate gastrin release.
• Include protein‑rich, non‑acidic foods (e.g., poultry, fish, beans).
• Stay hydrated—water helps dilute gastric contents.
• Consider a dietitian experienced with malabsorption for individualized plans.

Monitoring & follow‑up

• Serum gastrin level every 6–12 months (or sooner if symptoms change).
• Imaging (CT/MRI or DOTATATE PET) annually if tumor remains unresected.
• Bone density test every 2–3 years for patients on high‑dose PPIs.

Psychosocial support

• Join support groups (e.g., Neuroendocrine Tumor Research Foundation). Sharing experiences reduces anxiety.
• Seek counseling if chronic pain or medication side‑effects affect mental health.

Prevention

Because most gastrinomas are sporadic and arise from genetic mutations, primary prevention is limited. However, risk can be mitigated in the following ways:

• Family screening – relatives of patients with MEN‑1 should undergo genetic counseling and periodic gastrin testing.
• Early detection of H. pylori – eradication does not prevent ZES but removes a confounding ulcer cause, prompting earlier work‑up for atypical ulcers.
• Avoid chronic gastric irritants (excessive NSAIDs, alcohol) that could mask early symptoms.

Complications

If left untreated or inadequately controlled, ZES can lead to serious health problems:

• Perforated peptic ulcer – life‑threatening abdominal emergency.
• Severe gastrointestinal bleeding – may require transfusion or endoscopic therapy.
• Malabsorption & nutritional deficiencies – leading to weight loss, anemia, osteoporosis.
• Pancreatic or hepatic metastases – occur in up to 60 % of sporadic gastrinomas; reduce survival.
• Recurrent ulcer disease – can cause chronic pain and diminished quality of life.
• Secondary infections – chronic PPI use can predispose to Clostridioides difficile infection.

When to Seek Emergency Care

---

References:

1. G. D. H. Brose, et al. “Epidemiology of Gastrinomas and Zollinger‑Ellison Syndrome.” Neuroendocrine Tumors, 2020. PMCID: PMC5942690
2. Mayo Clinic. “Zollinger‑Ellison syndrome – Diagnosis and treatment.” Updated 2023. Mayo Clinic
3. American College of Gastroenterology. “Management guidelines for Zollinger‑Ellison syndrome.” Gastroenterology, 2022.
4. National Cancer Institute. “Pancreatic Neuroendocrine Tumors Treatment (PDQ®)”. 2024. NCI
5. World Health Organization. “Classification of Neuroendocrine Tumors.” 2023.

```